Holen Sie sich die Stockscreener-App
577.58
0.17%
-0.96
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$578.54
Offen:
$581.38
24-Stunden-Volumen:
463.84K
Relative Volume:
0.96
Marktkapitalisierung:
$25.31B
Einnahmen:
$3.18B
Nettoeinkommen (Verlust:
$1.33B
KGV:
20.70
EPS:
27.9001
Netto-Cashflow:
$1.04B
1W Leistung:
-0.71%
1M Leistung:
+7.73%
6M Leistung:
+33.64%
1J Leistung:
+102.79%
1-Tages-Spanne:
$575.00
$584.54
1-Wochen-Bereich:
$566.12
$584.54
52-Wochen-Spanne:
$272.12
$607.89
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
577.58 | 25.36B | 3.18B | 1.33B | 1.04B | 27.90 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 56.39B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
120.76 | 50.93B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.66 | 43.19B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.61 | 36.99B | 17.41B | 1.43B | 1.00B | 1.2182 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Underweight |
| 2025-09-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
| 2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-12-05 | Eingeleitet | Goldman | Sell |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-20 | Bestätigt | BofA Securities | Underperform |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Neutral |
| 2021-07-14 | Hochstufung | Argus | Hold → Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
| 2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
| 2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Hochstufung | UBS | Sell → Neutral |
| 2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
| 2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Bestätigt | Barclays | Underweight |
| 2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
| 2017-12-27 | Bestätigt | Wedbush | Outperform |
| 2017-04-27 | Bestätigt | Wedbush | Outperform |
| 2017-03-30 | Eingeleitet | UBS | Sell |
| 2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
UNITED THERAPEUTICS CORPORATION (UTHR) - MSN
Rothblatt, United Therapeutics CEO, sells $5.5 million in stock - Investing.com
Rothblatt, United Therapeutics CEO, sells $5.4m in UTHR stock By Investing.com - Investing.com India
Rothblatt, United Therapeutics CEO, sells $5.4m in UTHR stock - Investing.com
United Therapeutics stock surges 32% in 6 months: Here's why - MSN
UTHR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
United Therapeutics (NASDAQ:UTHR) Stock Rating Upgraded by Raymond James Financial - MarketBeat
Analyst Ratings Update: United Therapeutics (UTHR) Current Price Target Raised | UTHR Stock News - GuruFocus
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
Raymond James initiates United Therapeutics stock coverage with outperform rating - Investing.com Australia
Rothblatt Martine a of United Therapeutics sells $5.5M in UTHR stock - Investing.com Australia
Raymond James initiates United Therapeutics stock coverage with outperform rating By Investing.com - Investing.com South Africa
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.
United Therapeutics’ liver device gets FDA regenerative therapy status - Investing.com
Bioengineered liver for acute liver failure gets key FDA designation - Stock Titan
James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) CFO Sells $5,615,000.00 in Stock - MarketBeat
United Therapeutics CFO Edgemond sells $5.6m in UTHR stock By Investing.com - Investing.com Australia
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock By Investing.com - Investing.com Canada
United Therapeutics CFO Edgemond sells $5.6m in UTHR stock - Investing.com
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock - Investing.com
United Therapeutics rises on positive study for cornerstone drug. Why shares could run even higher - MSN
Perpetual Ltd Makes New Investment in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Element Squared LLC Acquires New Position in United Therapeutics Corporation $UTHR - MarketBeat
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Will United Therapeutics (UTHR) Surpass Expectations in Its Upcoming Earnings Announcement? - Bitget
United Therapeutics' Strong Competitive Edge and Robust Cash Flow Indicate a Sustainable Value Opportunity - Bitget
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,610,605.00 in Stock - MarketBeat
UNITED THERAPEUTICS CORP (UTHR.MX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate - Yahoo Finance
Allspring Global Investments Holdings LLC Has $52.05 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics: Maintaining 'Strong Buy' On Second TETON Study Program Win (UTHR) - Seeking Alpha
United Therapeutics Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
BKMC Volume Surges 38-Fold as United Therapeutics Jumps - TipRanks
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CFO exercises options and sells 10k shares - Stock Titan
UNITED THERAPEUTICS (UTHR) director exercises options and sells 1,300 shares under 10b5-1 plan - Stock Titan
UNITED THERAPEUTICS (UTHR) CEO sells 9,500 shares after option exercise - Stock Titan
United Therapeutics Corporation (UTHR) Stock forecasts - Yahoo Finance UK
Wells Fargo Raises Price Target for United Therapeutics (UTHR) t - GuruFocus
United Therapeutics (NASDAQ:UTHR) Price Target Raised to $660.00 at HC Wainwright - MarketBeat
United Therapeutics (UTHR): Analyst Greg Harrison Raises Price T - GuruFocus
United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo - 247wallst.com
Retirement Systems of Alabama Has $47.39 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last? - Yahoo Finance
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):